These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38484212)

  • 41. Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States.
    Bruno DS; Hess LM; Li X; Su EW; Patel M
    JCO Precis Oncol; 2022 Jun; 6():e2100427. PubMed ID: 35737912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).
    Liu SM; Yan HH; Wei XW; Lu C; Dong XR; Du Y; Cui JW; Chen Y; Ma R; Wang BH; Zhou Z; Cang SD; Yang JJ; Tu HY; Zhang XC; Zhong WZ; Zhou Q; Wu YL
    Clin Lung Cancer; 2022 Nov; 23(7):e395-e399. PubMed ID: 35659479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrating NGS-derived mutational profiling in the diagnosis of multiple lung adenocarcinomas.
    Ezer N; Wang H; Corredor AG; Fiset PO; Baig A; van Kempen LC; Chong G; Issac MSM; Fraser R; Spatz A; Riviere JB; Broët P; Spicer J; Camilleri-Broët S
    Cancer Treat Res Commun; 2021; 29():100484. PubMed ID: 34773797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.
    Bins S; Cirkel GA; Gadellaa-Van Hooijdonk CG; Weeber F; Numan IJ; Bruggink AH; van Diest PJ; Willems SM; Veldhuis WB; van den Heuvel MM; de Knegt RJ; Koudijs MJ; van Werkhoven E; Mathijssen RH; Cuppen E; Sleijfer S; Schellens JH; Voest EE; Langenberg MH; de Jonge MJ; Steeghs N; Lolkema MP
    Oncologist; 2017 Jan; 22(1):33-40. PubMed ID: 27662884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
    Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
    JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
    Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
    J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable
    Szpechcinski A; Moes-Sosnowska J; Skronska P; Lechowicz U; Pelc M; Szolkowska M; Rudzinski P; Wojda E; Maszkowska-Kopij K; Langfort R; Orlowski T; Sliwinski P; Polaczek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.
    Søreide K; Watson MM; Lea D; Nordgård O; Søreide JA; Hagland HR;
    J Transl Med; 2016 Jun; 14(1):192. PubMed ID: 27357108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
    Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
    Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.
    Kang DW; Park SK; Yu YL; Lee Y; Lee DH; Kang S
    ESMO Open; 2024 Jan; 9(1):102200. PubMed ID: 38194884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel.
    Tateo V; Cigliola A; Mercinelli C; Agarwal N; Grivas P; Kamat AM; Gibb EA; Moschini M; Brausi M; Dyrskjøt L; Loriot Y; Gupta S; Colecchia M; Spiess PE; Ross JS; Necchi A
    Clin Genitourin Cancer; 2024 Aug; 22(4):102091. PubMed ID: 38735133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
    Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
    Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
    Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
    Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.